Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616064 | 0.90 | KMT2A (0.39) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19615253 | 0.90 | KMT2A (0.39) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL23251275 | 0.88 | KMT2A (0.38) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL10427543 | 0.88 | KMT2A (0.41) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19635177 | 0.86 | KMT2A (0.41) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL15273711 | 0.86 | KMT2A (0.41) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19615389 | 0.84 | KMT2A (0.39) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19635116 | 0.84 | KMT2A (0.39) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19615867 | 0.84 | KMT2A (0.39) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL19615265 | 0.82 | KMT2A (0.38) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103044331-B | Prepare the new method of the formamide of 3 n-propyl pyrazoles of silaenafil intermediate 4 amino, 1 methyl 5 | 常州市亚邦医药研究所有限公司 | 2017-09-15 | — | — | CN | claimed |
| CN-103044331-A | Novel method for preparing Sildenafil intermediate 4-amino-1-methyl-3-n-propyl-pyrazole-5-formamide | CHANGZHOU YABANG PHARMACEUTICAL INST CO LTD | 2013-04-17 | — | — | CN | claimed |
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-109715632-B | Macrocyclic indole derivatives | 拜尔公开股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
| CN-103044331-B | Prepare the new method of the formamide of 3 n-propyl pyrazoles of silaenafil intermediate 4 amino, 1 methyl 5 | 常州市亚邦医药研究所有限公司 | 2017-09-15 | — | — | CN | disclosed |
| CN-103044331-A | Novel method for preparing Sildenafil intermediate 4-amino-1-methyl-3-n-propyl-pyrazole-5-formamide | CHANGZHOU YABANG PHARMACEUTICAL INST CO LTD | 2013-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | SMN1; SMN2 4099/4885RAB9A 2496/4885NPC1 1636/4885 |
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | SMN1; SMN2 4139/4885RAB9A 2157/4885NPC1 1619/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | SMN1; SMN2 4202/4885RAB9A 2378/4885NPC1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.